Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?

Novo Nordisk's Wegovy GLP-1 weight-loss pill has surpassed 5 million prescriptions and is outperforming the company's injectable version, supporting its strategic shift to a volume-driven business model. However, the company faces headwinds from lower pricing, weak earnings, and intensifying competition from Eli Lilly's rival GLP-1 pill. The stock offers an attractive 4.4% dividend yield and historically cheap valuation, making it appealing for aggressive dividend investors willing to bet on the turnaround, though more conservative investors should wait for clearer progress on profitability.